BridgeBio CAO has 4,714 shares withheld for taxes

BridgeBio Pharma, Inc. Chief Accounting Officer Maricel Apuli reported a share disposition tied to tax withholding on vested equity awards.

Rhea-AI Filing Summary

BridgeBio Pharma, Inc. Chief Accounting Officer Maricel Apuli reported a share disposition tied to tax withholding on vested equity awards. On May 16, 2026, 4,714 shares of common stock were withheld at $66.13 per share to satisfy her tax obligation on the vesting of 9,260 RSU-based shares. After this withholding, she directly held 129,401 shares of BridgeBio common stock. This type of transaction is used to cover taxes on compensation-related stock vesting rather than representing an open‑market sale.

Insider Trade Summary

Exercise Price or Tax Liability: 4,714 shares

Exercise Price or Tax Liability 1 txn

Insider Apuli Maricel

Role Chief Accounting Officer

Type	Security	Shares	Price	Value
Exercise Price or Tax Liability	Common Stock	4,714	$66.13	$312K

Holdings After Transaction: Common Stock — 129,401 shares (Direct)

Footnotes (1)

1. F1. Represents number of shares of the Issuer's Common Stock withheld to satisfy the Reporting Person's tax obligation in connection with the vesting of 9,260 shares of Common Stock underlying the Reporting Person's RSUs.

Key Figures

Shares withheld for taxes: 4,714 shares Withholding price: $66.13 per share RSU-based shares vested: 9,260 shares +1 more

4 metrics

Shares withheld for taxes 4,714 shares Withheld on May 16, 2026 to satisfy tax obligation

Withholding price $66.13 per share Value used for tax-withholding disposition of 4,714 shares

RSU-based shares vested 9,260 shares Common stock underlying RSUs that vested, triggering withholding

Shares held after transaction 129,401 shares Direct BridgeBio common stock holdings following withholding

Key Terms

RSUs, tax obligation, withheld, vesting

4 terms

RSUs financial

"underlying the Reporting Person's RSUs"

RSUs, or restricted stock units, are a form of company shares given to employees as part of their compensation. They are typically awarded with certain restrictions, such as a waiting period before they can be fully owned or sold, similar to earning a gift that becomes fully yours over time. For investors, RSUs can impact a company's stock offerings and reflect how much the company relies on stock-based incentives to attract and retain talent.

tax obligation financial

"withheld to satisfy the Reporting Person's tax obligation in connection with the vesting"

withheld financial

"Represents number of shares of the Issuer's Common Stock withheld to satisfy"

vesting financial

"in connection with the vesting of 9,260 shares of Common Stock"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did BridgeBio Pharma (BBIO) report for Maricel Apuli?

BridgeBio’s Chief Accounting Officer Maricel Apuli reported a tax-related share disposition. The company withheld 4,714 shares of common stock to cover taxes due on the vesting of 9,260 RSU-based shares granted as compensation.

Did Maricel Apuli sell BridgeBio (BBIO) shares on the open market?

No, the filing shows no open-market sale. Instead, 4,714 BridgeBio shares were withheld by the company at $66.13 per share to satisfy Apuli’s tax obligation arising from the vesting of 9,260 RSU-based shares.

How many BridgeBio (BBIO) shares does Maricel Apuli hold after this Form 4 transaction?

Following the tax-withholding transaction, Maricel Apuli directly holds 129,401 shares of BridgeBio common stock. This figure reflects her position after 4,714 shares were withheld to cover taxes on recently vested RSU-based shares.

What triggered the tax-withholding disposition in BridgeBio (BBIO) insider filing?

The disposition was triggered by the vesting of 9,260 shares of common stock underlying Maricel Apuli’s RSUs. To cover her tax obligation from this vesting, 4,714 BridgeBio shares were withheld instead of selling shares in the open market.

What was the price used for the withheld BridgeBio (BBIO) shares in this Form 4?

The withheld BridgeBio shares were valued at $66.13 per share. At that price, 4,714 shares were retained by the company to satisfy Maricel Apuli’s tax liability linked to the vesting of 9,260 RSU-based shares.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/19/2026 - 04:26 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Apuli Maricel

(Last) (First) (Middle)

C/O BRIDGEBIO PHARMA, INC.

3160 PORTER DR., SUITE 250

(Street)

PALO ALTO CALIFORNIA 94304

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
BridgeBio Pharma, Inc. [ BBIO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Accounting Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/16/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	05/16/2026		F		4,714(1)	D	$66.13	129,401	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents number of shares of the Issuer's Common Stock withheld to satisfy the Reporting Person's tax obligation in connection with the vesting of 9,260 shares of Common Stock underlying the Reporting Person's RSUs.

Remarks:

	/s/ Maricel Apuli	05/19/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)